We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

BD, CerTest Biotec Announce Commercial Launch of Monkeypox Test

By LabMedica International staff writers
Posted on 31 Jul 2022
Image: The RUO assay is now available for the BD MAX System (Photo courtesy of BD)
Image: The RUO assay is now available for the BD MAX System (Photo courtesy of BD)

Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) and CerTest Biotec (Zaragoza, Spain) have announced their newly developed molecular polymerase chain reaction (PCR) test for the monkeypox virus is now commercially available outside of the US for use in research applications by laboratories. The assay leveraged the BD MAX System open system reagent suite to develop the CerTest VIASURE Monkeypox molecular test on the BD MAX System.

The BD MAX System is a fully integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in less than three hours. BD offers an extensive menu of tests on the system covering health care associated infections, respiratory infections, sexually transmitted infections, gastrointestinal infections and women's health. BD offers a suite of open system reagents for the BD MAX System that enables labs to fully automate and streamline their Lab Developed Tests. As with all CerTest tests, the Monkeypox PCR Detection Kit for the BD MAX System is offered in a lyophilized format. Accordingly, the test will come in a tube that snaps into the test-specific position on the BD MAX ExK TNA extraction strip, which is supplied by BD.

"One of the key advantages of the BD MAX System is its open-architecture system that enables rapid response to emerging health threats," said Nikos Pavlidis, vice president of Molecular Diagnostics at BD. "Just as we did at the beginning of the COVID-19 pandemic, we partnered with CerTest to quickly develop a molecular test to help better understand and track this disease."

"Speed is of the essence when responding to what the World Health Organization has declared a global health emergency," Nelson Fernandes, managing director of CerTest Biotec. "We hope this new test will boost capacity for monkeypox research, ultimately helping quell the spread of the disease."

Related Links:
BD 
CerTest Biotec

New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit

Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
GLOBE SCIENTIFIC, LLC